We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

133 hedge funds and large institutions have $1.3B invested in Intra-Cellular Therapies Inc. in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 47 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

337% more capital invested

Capital invested by funds: $298M → $1.3B (+$1B)

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

6% more funds holding

Funds holding: 126 → 133 (+7)

23% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 47

53% less call options, than puts

Call options by funds: $260M | Put options by funds: $549M

Holders
133
Holders Change
+7
Holders Change %
+5.56%
% of All Funds
2.62%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.08%
New
31
Increased
36
Reduced
47
Closed
24
Calls
$260M
Puts
$549M
Net Calls
-$289M
Net Calls Change
-$278M

Top Buyers

1
CCM
Consonance Capital Management
New York
+$23.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$14.6M
3
ACP
Acuta Capital Partners
California
+$7.05M
4
VMI
VHCP Management III
New York
+$6.9M
5
OM
Opaleye Management
Massachusetts
+$2.84M

Top Sellers

1
WA
Wasatch Advisors
Utah
-$26.8M
2
Millennium Management
Millennium Management
New York
-$11.7M
3
SC
Samlyn Capital
New York
-$11M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$8.11M
5
ClearBridge Investments
ClearBridge Investments
New York
-$5.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
GRP
126
Global Retirement Partners
California
$17K -$5.13K -427 -46%
CG
127
Cutler Group
California
$17K +$3.6K +300 +150%
Daiwa Securities Group
128
Daiwa Securities Group
Japan
$10K – – –
WEC
129
Winslow Evans & Crocker
Massachusetts
$10K – – –
LTFS
130
Ladenburg Thalmann Financial Services
Florida
$5K – – –
LWANC
131
Laurel Wealth Advisors (North Carolina)
North Carolina
$5K – – –
LP
132
LMR Partners
United Kingdom
$3.43K +$1.2M +100,000 New
TPCW
133
TD Private Client Wealth
New York
$1.34K +$468 +39 New
Point72 Asset Management
134
Point72 Asset Management
Connecticut
– -$4.18M -559,900 Closed
Squarepoint
135
Squarepoint
New York
– -$1.1M -147,257 Closed
Verition Fund Management
136
Verition Fund Management
Connecticut
– -$1.42M -118,091 Closed
PVI
137
Pura Vida Investments
New York
– -$815K -109,130 Closed
DekaBank Deutsche Girozentrale
138
DekaBank Deutsche Girozentrale
Germany
– -$493K -65,700 Closed
Group One Trading
139
Group One Trading
Illinois
– -$639K -53,244 Closed
BCM
140
Bluefin Capital Management
New York
– -$512K -42,649 Closed
GCP
141
GSA Capital Partners
United Kingdom
– -$312K -41,823 Closed
HSBC Holdings
142
HSBC Holdings
United Kingdom
– -$274K -36,654 Closed
CSS
143
Cubist Systematic Strategies
Connecticut
– -$248K -33,234 Closed
Connor, Clark & Lunn Investment Management (CC&L)
144
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$198K -26,556 Closed
CBA
145
Coastal Bridge Advisors
Connecticut
– -$161K -21,605 Closed
TI
146
Trexquant Investment
Connecticut
– -$137K -18,383 Closed
QT
147
Quantbot Technologies
New York
– -$98K -13,174 Closed
DTL
148
Dynamic Technology Lab
Singapore
– -$88K -11,716 Closed
CPP
149
Crow Point Partners
Massachusetts
– -$86K -11,499 Closed
NIT
150
NumerixS Investment Technologies
British Columbia, Canada
– -$81K -10,800 Closed
3 4 5
6
7

ITCI Hedge Fund Activity: Q4 2019 in Review

133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2019, worth a combined $1.3B — up 337% from $298M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ITCI positions and 24 closed out — a net gain of 7 holders — while 36 added to existing stakes and 47 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $23.5M. The largest seller was Wasatch Advisors, cutting an estimated $26.8M.

  • 133 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2019, up from 126 in Q3 2019.
  • Funds reported $1.3B of Intra-Cellular Therapies Inc. stock for Q4 2019, up 337% quarter-over-quarter.
  • 31 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2019 and 24 closed out, a net change of +7 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2019 was Consonance Capital Management, an estimated $23.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2019 was Wasatch Advisors, an estimated $26.8M sold.

Based on aggregated 13F filings for Q4 2019.